Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV

Executive Summary

FDA's decision to proceed with an Institute of Medicine review of drug safety regulation could trigger a full-fledged debate over the possibility of creating a separate post-marketing regulatory agency in the U.S

You may also be interested in...



IoM Drug Safety Report Recommends Sweeping Changes At CDER

FDA's Center for Drug Evaluation & Research is "an organization in urgent need of great change," the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee concludes in a final report issued Sept. 22

IoM Drug Safety Report Recommends Sweeping Changes At CDER

FDA's Center for Drug Evaluation & Research is "an organization in urgent need of great change," the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee concludes in a final report issued Sept. 22

FDA Gets Permanent Drug Safety Director In Advance Of Drug Center Overhaul

FDA's Office of Drug Safety will take on a higher profile position under a proposed reorganization of the Center for Drug Evaluation & Research

Related Content

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel